Trial · NCT06012435
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435, Phase 3, Active not recruiting, Seagen, a wholly owned subsidiary of Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer. Trials, record NCT06012435. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06012435
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- NCT number
- NCT06012435
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 762 participants, actual
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- sigvotatug vedotin, docetaxel
- First posted
- 2023-08-25
- Last updated
- 2026-07-23
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel) | Approximately 5 years | The time from date of randomization to date of death due to any cause. |
| Secondary | Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR) | Approximately 5 years | The time from date of randomization to the first documented disease progression per RECIST v1.1 or to death due to any cause. |
| Secondary | PFS per RECIST v1.1 by investigator assessment | Approximately 5 years | The time from date of randomization to the first documented disease progression per RECIST v1.1 or to death due to any cause. |
| Secondary | Confirmed Objective Response Rate (ORR) per RECIST v1.1 as assessed by BICR | Approximately 5 years | The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1. |
| Secondary | Confirmed ORR per RECIST v1.1 by investigator assessment | Approximately 5 years | The proportion of participants with confirmed CR or PR according to RECIST v1.1. |
| Secondary | Duration of Response (DOR) per RECIST v1.1 by BICR | Approximately 5 years | The time from the first documented objective response (CR or PR that is subsequently confirmed) to the first documented disease progression per RECIST v1.1 or to death due to any cause. |
| Secondary | DOR per RECIST v1.1 by investigator assessment | Approximately 5 years | The time from the first documented objective response (CR or PR that is subsequently confirmed) to the first documented disease progression per RECIST v1.1 or to death due to any cause. |
| Secondary | Number of participants with adverse events (AEs) | Through 30 days after the last study intervention; Approximately 5 years | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
| Secondary | Mean score in the global health status/QoL combined score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Approximately 5 years | The EORTC QLQ-C30 was developed as a quantitative measure of health-related quality of life (HRQoL). Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
| Secondary | Change from baseline in global health status/QoL combined score on the EORTC QLQ-C30 | Approximately 5 years | The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06012435
GET https://conductscience.org/api/trials/v1/NCT06012435/registered